Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Obesity therapies and the multi-indication momentum: how industry is responding
The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their potential across a spectrum of interconnected conditions. New data reveals how the breakthrough has sparked a major shift toward multi-indication drug development.
-
ICON launches multi-indication trial design service for obesity drugs
Clinical trial designs for obesity treatments should accommodate candidate drugs that have the potential to treat multiple conditions, or developers risk missing opportunities, according to Irish CRO ICON.
-
More efficient next-gen obesity clinical trials needed, says survey
In this DDW article, discover key findings of an ICON survey focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities.
-
Pharma giants eye obesity trial boom — but are they ready for what comes next?
ICON survey shows pharma's enthusiasm for multi-indication obesity trials is outpacing trial design readiness.
-
The challenge of targeting chronic inflammation in obesity
In this article, ICON experts explore the connection of obesity and inflammation, the current treatment landscape and future treatment directions.
-
Expanding diagnostic and biomarker options to improve MASH clinical trials
The absence of sufficient and accessible diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) studies can complicate trials and impair clinical study conduct, as diagnostics are essential for disease detection, confirmation, and monitoring.
-
Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
Liver disease, obesity and the value of treatment
This article by Dr Alan Baldridge and Jolanta M. Wichary, discusses the link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
-
Pharma’s obsession with obesity on rise
ICON experts, Jack Martin and Simon Bruce share insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
